Townsend Letter The Examiner of Alternative Medicine
Alternative Medicine Conference Calendar
Check recent tables of contents


From the Townsend Letter
October 2006


Recent Progress in Clinical Applications
and Research in Fibromyalgia

by Robert W. Bradford, Professor of Medicine, D. Sc. NMD, and Henry W. Allen, Director of Clinical Biochemistry, BRI

Search this site

The article. . . 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

Table of Contents

(Page 1, Page 2)

1. Bradley LA, McKendree-Smith NL, Alarcon GS. Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome. Curr Rev Pain. 2000;4:148-157.
2. Pongratz DE. Sievers M. Fibromyalgia-symptom or diagnosis: a definition of the position. Scand J Rheumatol (Suppl). 2000;113:3-7.
3. Harding SM. Sleep in fibromyalgia patients: subjective and objective findings. Am J Med Sci. 1998;315:367-76.
4. Korszun A. Sleep and circadian rhythm disorders in fibromyalgia. Curr Rheumatol Rep. 2000;2:124-30.
5. Buskila D, Neumann L, Alhoashle A, et al. Fibromyalgia syndrome in men. Semin Arthritis Rheum. 2000;30:47-51.
6. Anderberg UM, Marteinsdottir I, Theorell T, et al. The impact of life events in female patients with fibromyalgia and in female healthy controls. Eur Psychiatry. 2000;15:295-301.
7. Jeschonneck M, Grohmann G, Hein G, et al. Abnormal microcirculation and temperature in skin above tender points in patients with fibromyalgia. Rheumatology (Oxford). 2000;39:917-21.
8. Shanklin DR, Stevens MV, Hall MF, et al. Environmental immunogens and T-cell-mediated responses in fibromyalgia: evidence for immune dysregulation and determinants of granuloma formation. Exp Mol Pathol. 2000;69:102-18.
9. Pongratz DE, Spath M. Morphologic aspects of fibromyalgia. Z Rheumatol. 1998;57 Suppl 2:47-51.
10. Kwiatek R, Barnden L, Tedman R, et al. Regional cerebral blood flow in fibromyalgia: single-photon-emission computed tomography evidence of reduction in the pontine tegmentum and thalami. Arthritis Rheum. 2000;43:2823-33.
11. Bradley LA, McKendree-Smith NL, Alberts KR, et al. Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Curr Rheumatol Rep. 2000;2:141-148.
12. Neeck G. Neuroendocrine and hormonal perturbations and relations to the serotonergic system in fibromyalgia patients. Scand J Rheumatol (Suppl). 2000;113:8-12.
13. Ackenheil M. Genetics and pathophysiology of affective disorders: relationship to fibromyalgia. Z Rheumatol. 1998;57 Suppl 2:5-7.
14. Bondy B, Spaeth M, Offenbaecher M, et al. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis. 1999;6:433-9.
15. Wikner J, Hirsch U, Wetterberg L, et al. Fibromyalgia- a syndrome associated with decreased nocturnal melatonin secretion. Clin Endocrinol (Oxford). 1998;49:179-83.
16. Klein R, Berg PA. High incidence of antibodies to 5-hydroxytryptamine, gangliosides and phospholipids in patients with chronic fatigue and fibromyalgia syndrome and their relatives: evidence for a clinical entity of both disorders. Eur J Med Res. 1995;1:21-6.
17. Coplan JD, Tamir H, Calaprice D, et al. Plasma anti-serotonin and serotonin anti-idiotypic antibodies are elevated in panic disorder. Neuropsychopharmacology. 1999;20:386-91.
18. Klein R, Bansch M, Berg PA. Clinical relevance of antibodies against serotonin and gangliosides in patients with primary fibromyalgia syndrome. Psychoneuroendocrinology. 1992;17:593-8.
19. Wolfe F, Russell IJ, Vipraio G, et al. Serotonin levels, pain threshold, and fibromyalgia symptoms in the general population. J Rheumatol. 1997;24:555-9.
20. Ernberg M, Hedenberg-Magnusson B, Alstergren P, et al. The level of serotonin in the superficial masseter muscle in relation to local pain and allogynia. Life Sci. 1999;65:313-25.
21. Khawaja AM, Rogers DF. Tachykinins: receptor to effector. Int J Biochem Cell Biol. 1996;28:721-38.
22. Murphey R. Primary amino acid sequence of guinea-pig substance P. Neuropeptides. 1989;14:105-10.
23. Lee S, Suh YH, Kim S, et al. Comparison of the structures of beta amyloid peptide (25-35) and substance P in trifluoroethanol/water solution. J Biomol Struct Dyn. 1999;17:381-91.
24. Patel AB, Srivastava S, Coutinho E, et al. Replacement of phe(8) in substance P by tyr (Tyr(8)-SP) alters the conformation of the peptide in DMSO, water, and lipid bilayers. Biopolymers. 1999;50:602-12.
25. Cowsik SM, Lucke C, Ruterjans H. Lipid-induced conformation of substance P. J Biomol Struct Dyn. 1997;15:27-36.
26. Ploux O, Lavielle S, Chassaing G, et al. Interaction of tachykinins with their receptors studied with cyclic analogues of substance P and neurokinin B. Proc Natl Acad Sci U S A. 1987;84:8095-9.
27. Takeuchi Y, Shands EF, Beusen DD, et al. Derivation of a three-dimensional pharmacophore model of substance P antagonists bound to the neurokinin-1 receptor. J Med Chem. 1998;41:3609-23.
28. Grdadolnik SG, Mierke DF, Byk G, et al. Comparison of the conformation of active and nonactive backbone cyclic analogs of substance P as a tool to elucidate features of the bioactive conformation: NMR and molecular dynamics in DMSO and water. J Med Chem. 1994;37:2145-52.
29. Meiworm L, Jakob E, Walker UA, et al. Patients with fibromyalgia benefit from aerobic endurance exercise. Clin Rheumatol. 2000;19:253-7.
30. Sprott H, Franke S, Kluge H, et al. Pain treatment of fibromyalgia by acupuncture. Rheumatol Int. 1998;18:35-6.
31. Maes M, Verkerk R, Delmeire L, et al. Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. Psychiatry Res. 2000;97:11-20.
32. Citera G, Arias MA, Maldonado-Cocco JA, et al. The effect of melatonin in patients with fibromyalgia: a pilot study. Clin Rheumatol. 2000;19:9-13.
33. Merchant RE, Carmack CA, Wise CM. Nutritional supplementation with Chlorella pyrenoidosa for patients with fibromyalgia syndrome: a pilot study. Phytother Res. 2000;14:167-73.
34. Wolf H. Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists. Scand J Rheumatol (Suppl). 2000;113:37-45.
35. Hrycaj P, Stratz T, Mennet P, et al. Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome – a preliminary study. J Rheumatol. 1996;23:1418-23.
36. O'Malley PG, Balden E, Tomkins G, et al. Treatment of fibromyalgia with antidepressants. A meta-analysis. J Gen Intern Med. 2000;15:659-66.
37. Goldenberg D, Mayskiy M, Mossey C, et al. A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum. 1996;39:1852-9.
38. Lautenschlager J. Present state of medication therapy in fibromyalgia syndrome. Scand J Rheumatol (Suppl). 2000;113:32-6.
39. Ninan PT. Use of venlafaxine in other psychiatric disorders. Depress Anxiety. 2000;12 Suppl 1:90-4.
40. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998;3:271-80.
41. Haus U, Varga B, Stratz T, et al. Oral treatment of fibromyalgia with tropisetron given over 28 days: influence on functional and vegetative symptoms, psychometric parameters and pain. Scand J Rheumatol (Suppl). 2000;113:55-8.
42. Farber L, Stratz T, Bruckle W, et al. Efficacy and tolerability of tropisetron in primary fibromyalgia – a highly selective and competitive 5-HT3 receptor antagonist. German Fibromyalgia Study Group. Scand J Rheumatol (Suppl). 2000;113:49-54.
43. Muller W, Stratz T. Results of the intravenous administration of tropisetron in fibromyalgia patients. Scand J Rheumatol (Suppl). 2000;113:59-62.
44. De Simone C. Misefari A, Covelli V, et al. Effects of substance P on the spontaneous binding of Salmonella minnesota R345 (Rb) to human peripheral blood lymphocytes. J Clin Lab Anal. 1989;3:345-9.
45. Annunziata P, Cioni C, Toneatto S, et al. HIV-1 gp120 increases the permeability of rat brain endothelium cultures by a mechanism involving substance P. AIDS. 1998;12:2377-85.
46. Nasralla M, Haier J, Nicolson GL. Multiple mycoplasmal infections detected in blood of patients with chronic fatigue syndrome and/or fibromyalgia syndrome. Eur J Clin Microbiol Infect Dis. 1999;18:859-65.
47. Dionisio D, Valassina M, Mata S, et al. Encephalitis caused directly by Mycoplasma pneumoniae. Scand J Infect Dis. 1999;31:506-9.
48. Komatsu H, Kuroki S, Shimizu Y, et al. Mycoplasma pneumoniae meningoencephalitis and cerebellitis with antiganglioside antibodies. Pediatr Neurol. 1998;18:160-4.
49. Caceres ME, de los Reyes EC, Khan R, et al. Acute encephalopathy and intractable seizures in a 10-year-old boy. Semin Pediatr Neurol. 1999;6:229-31.
50. Launes J, Paetau A, Linnavuori K, et al. Direct invasion of the brain parenchyma by Mycoplasma pneumoniae. Acta Neurol Scand. 1997;95:374.
51. Yirmiya R, Weidenfeld J, Barak O, et al. The role of brain cytokines in mediating the behavioral and neuroendocrine effects of intracerebral Mycoplasma fermentans. Brain Res. 1999;829:28-38.
52. Buskila D, Shnaider A, Neumann L, et al. Fibromyalgia in hepatitis C virus infection. Another infectious disease relationship. Arch Intern Med. 1997;157:2497-500.
53. Rivera J, de Diego A, Trinchet M, et al. Fibromyalgia-associated hepatitis C virus infection. Br J Rheumatol. 1997;36:981-5.
54. Machtey I. Chlamydia pneumoniae antibodies in myalgia of unknown cause (including fibromyalgia). Br J Rheumatol. 1997;36:1134.
55. Meyer RD, Kaplan MH, Ong M, et al. Cutaneous lesions in disseminated mucormycosis. JAMA. 1973;225:737-8.
56. Taylor-Robinson D, Furr PM, Davies HA, et al. Mycoplasmal adherence with particular reference to the pathogenicity of Mycoplasma pulmonis. Isr J Med Sci. 1981;17:599-603.
57. Kahane I, Pnini S, Banai M, et al. Attachment of mycoplasmas to erythrocytes: a model to study mycoplasma attachment to the epithelium of the host respiratory tract. Isr J Med Sci. 1981;17:589-92.
58. Shinriki N, Ishizaki K, Ikehata A, et al. Mode of degradation of tRNAs with ozone. Nucleic Acids Symp Ser. 1981;24:211-4.
59. Bradford RW, Allen HW, Hildreth DJ. The significance of fungemia in modern clinical experience. BRI Monograph #56. 1999, Bradford Research Institute, 1180 Walnut Ave., Chula Vista, California 91911.
60. Bradford RW, Allen HW. The Biochemical Basis of Live Cell Therapy. Chula Vista, California: The Robert W. Bradford Foundation, 1986.
61. Bradford RW, Allen HW. Inter-Reaction of Neuro-Endocrine Systems in Stress, Pathology and Peripheral Blood Morphology. Bradford Research Institute Monograph #59, 55 pgs.
62. Waylonis GW, Heck W. Fibromyalgia syndrome: New associations. Am J Phys Med Rehabil. 1992;71:343-8.
63. Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain. 1996;68:375-83.
64. Dinerman H, Goldenberg DL, Felson DT. A prospective evaluation of 118 patients with the fibromyalgia syndrome: prevalence of Raynaud's phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction. J Rheumatol. 1986;13:368-73.
65. Bell IR, Baldwin CM, Schwartz GE. Illness from low levels of environmental chemicals: relevance to chronic fatigue syndrome and fibromyalgia. Am J Med. 1998;105(3A):74S-82S.
66. Maes M, Libbrecht I, Van Hunsel F, et al. The immune-inflammatory pathophysiology of fibromyalgia: increased serum soluble gp130, the common signal transducer protein of various neurotropic cytokines. Psychoneuroendocrinology. 1999;24:371-83.
67. Deodhar AA, Figher RA, Blacker CV, et al. Fluid retention syndrome and fibromyalgia. Br J Rheumatol. 1994;33:576-82.
68. Pesle G, Triboulet F, Gharbi N, et al. About 35 cases of pleural aspergillosis. Ooumon Coeur. 1980;36:7-11.
69. Roux JP, Koussa A, Cajot MA, et al. Primary Aspergillus endocarditis. Apropos of a case and review of the international literature. Ann Chir. 1992;46:110-5.
70. Eberle DE, Evans RB, Johnson RH. Disseminated North American blastomycosis. Occurrence with clinical manifestations of adrenal insufficiency. JAMA. 1977;238:2629-30.
71. Helm TN, Longworth DL, Hall GS, et al. Case report and review of resolved fusariosis. J Am Acad Dermatol. 1990;23:393-8.
72. Harrison TS, Nong S, Levitz SM. Induction of human immunodificiency virus type 1 expression in monocytic cells by Cryptococcus neoformans and Candida albicans. J Infect Dis. 1997;176:485-91.
73. Huffnagle GB, Chen GH, Curtis JL, et al. Down-regulation of the afferent phase of T cell-mediated pulmonary inflammation and immunity by a high melanin-producing strain of Cryptococcus neoformans. J Immunol. 1995;155:3507-16.
74. Matthews R, Burnie J. The role of hsp90 in fungal infections. Immunol Today. 1992;13:345-8.
75. Tournas VH, Stack ME. Production of alternariol and alternariol methyl ether by Alternaria alternata grown on fruits at various temperatures. J Food Prot. 2001;64:528-32.
76. Li FQ, Toyazaki N, Yoshizawa T. Production of alternaria mycotoxins by Alternaria alternata isolated from weather-damaged wheat. J Food Prot. 2001;64:567-71.
77. Personal communication. Norbert Becquet, MD, Little Rock, AK, Prof. Robert W. Bradford, et al. Ingles Integrative Medical Hospital, Mexico, Albert MacKenzie, MD, Los Angeles, CA, Prof. Ann Marie Dixon, NMD, et al. Washington, DC.
78. Nicolson, GL, et al. Med Sentinel. 1999;4:172-6.
79. Buchanan KL, Murphy JW, What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis. 1998;4:71-83.
80. Wang Y, Aisen P, Casadevall A. Melanin, melanin "ghosts", and melanin composition in Cryptococcus neoformans. Infect Immun. 1996;64:2420-4.

Continued on Page 2

Consult your doctor before using any of the treatments found within this site.

Subscriptions are available for Townsend Letter, the Examiner of Alternative Medicine magazine, which is published 10 times each year.

Search our pre-2001 archives for further information. Older issues of the printed magazine are also indexed for your convenience.
1983-2001 indices ; recent indices

Once you find the magazines you'd like to order, please use our convenient form, e-mail, or call 360.385.6021 (PST).


Order back issues
Advertise with TLDP!
Visit our pre-2001 archives
© 1983-2006 Townsend Letter for Doctors & Patients
All rights reserved.
Web site by Sandy Hershelman Designs
September 11, 2006